Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study

被引：0

作者：

Coleman, Robert ^{[1
]}

Oaknin, Ana ^{[2
]}

Pignata, Sandro ^{[3
]}

Denys, Hannelore ^{[4
]}

Colombo, Nicoletta ^{[5
]}

Van Gorp, Toon ^{[6
]}

Konner, Jason ^{[7
]}

Marin, Margarita Romeo ^{[8
]}

Harter, Philipp ^{[9
]}

Murphy, Conleth ^{[10
]}

Esteves, Brooke ^{[11
]}

Method, Michael ^{[11
]}

Lorusso, Domenica ^{[12
]}

Matulonis, Ursula ^{[13
]}

机构：

[1] US Oncol Res, The Woodlands, TX USA

[2] Vall Hebron Inst Oncol, Barcelona, Spain

[3] Ist Nazl Tumori Napoli Fdn G Pascale, Naples, Italy

[4] Ghent Univ Hosp, Ghent, Belgium

[5] European Inst Oncol IRCCS, Milan, Italy

[6] Univ Hosp Leuven, Leuven, Belgium

[7] Mem Sloan Kettering Canc Ctr, New York, NY USA

[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[9] Kliniken Essen Mitte, Essen, Germany

[10] Bon Secours Hosp Cork & Canc Trials, Cork, Ireland

[11] ImmunoGen Inc, Waltham, MA USA

[12] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

[13] Dana Farber Canc Inst, Boston, MA USA

来源：

GYNECOLOGIC ONCOLOGY | 2023年 / 176卷

关键词：

D O I：

10.1016/j.ygyno.2023.06.468

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

002

引用

页码：S3 / S3

页数：1

共 50 条

[41] PICCOLO: AN OPEN-LABEL, SINGLE ARM, PHASE 2 STUDY OF MIRVETUXIMAB SORAVTANSINE IN RECURRENT PLATINUM SENSITIVE, HIGH-GRADE EPITHELIAL OVARIAN CANCERS WITH HIGH FOLATE-ALPHA EXPRESSION
Secord, Angeles Alvarez
Lewin, Sharon
Method, Michael
Murphy, Conleth
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A232 - A233
[42] Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
Moore, Kathleen N.
Angelergues, Antoine
Konecny, Gottfried E.
Banerjee, Susana N.
Pignata, Sandro
Colombo, Nicoletta
Moroney, John William
Cosgrove, Casey
Lee, Jung-Yun
Roszak, Andrzej
Breuer, Shani
Tromp, Jacqueline Maria
Bello-Roufai, Diana
Gilbert, Lucy
Miller, Rowan
Myers, Tashanna K. N.
Wang, Yuemei
Berkenblit, Anna
Lorusso, Domenica
Van Gorp, Toon
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[43] Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
Moore, Kathleen N.
Angelergues, Antoine
Konecny, Gottfried E.
Banerjee, Susana N.
Pignata, Sandro
Colombo, Nicoletta
Moroney, John William
Cosgrove, Casey
Lee, Jung-Yun
Roszak, Andrzej
Breuer, Shani
Tromp, Jacqueline Maria
Bello-Roufai, Diana
Gilbert, Lucy
Miller, Rowan
Myers, Tashanna K. N.
Wang, Yuemei
Berkenblit, Anna
Lorusso, Domenica
Van Gorp, Toon
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA5507 - LBA5507
[44] The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer
Liu, Joyce F.
Doshi, Kshama A.
Lee, Benjamin H.
Peluso, Marisa O.
Zhang, Li
Zhou, Shan
Zeng, Qing
Wang, Stephen
Kirschmeier, Paul T.
Tran, Cam A.
Paweletz, Cloud
Rausch, Matthew
Paterson, Alison M.
Gokhale, Prafulla C.
Matulonis, Ursula A.
CANCER RESEARCH, 2020, 80 (16)
[45] Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
O'Malley, D.
Richardson, D.
Vergote, I. B.
Gilbert, L.
Martin, L. P.
Mantia-Smaldone, G. M.
Castro, C.
Provencher, D.
Matulonis, U. A.
Malek, K.
Moore, K. N.
ANNALS OF ONCOLOGY, 2019, 30
[46] Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
Moore, Kathleen N.
Martin, Lainie P.
Seward, Shelly Marie
Bauer, Todd Michael
O'Malley, David M.
Perez, Raymond P.
Oza, Amit M.
Jeong, Woondong
Kirby, Maurice William
Zhou, Yinghui
Michenzie, Mary F.
Ponte, Joseph
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[47] A phase II trial of TPIV200 (a polypeptide vaccine against folate receptor alpha) plus durvalumab (anti-PD-L1 antibody) in patients with platinum-resistant ovarian cancer
Yeku, O.
Zamarin, D.
Gallagher, J.
Aghajanian, C. A.
Konner, J.
GYNECOLOGIC ONCOLOGY, 2018, 149 : 56 - 57
[48] Phase I study of MORAb-003, a humanized anti-folate receptor-alpha monoclonal antibody, in platinum resistant ovarian cancer.
Konner, J. A.
Ahmed, S.
Gerst, S.
Els, N. Vander
Pezzuli, S.
Sabbatini, P.
Hensley, M.
Dupont, J.
Tew, W.
Aghajanian, C.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 262S - 262S
[49] MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression
Moore, Kathleen
Konecny, Gottfried
Martin, Lainie
Floquet, Anne
O'Malley, David
Colombo, Nicoletta
Mantia-Smaldone, Gina
Banerjee, Susana
Gilbert, Lucy
de Gregorio, Nikolaus
Tromp, Jacqueline
Wang, Jiuzhou
Esteves, Brooke
Method, Michael
Van Gorp, Toon
GYNECOLOGIC ONCOLOGY, 2022, 166 : S156 - S157
[50] Topotecan in platinum-resistant advanced ovarian cancer (AOC) patients:: Evaluation of activity and prognostic factors of response. Preliminary results:: A study of the Spanish Group for Research on Ovarian Cancer (GEICO).
Soriano, V
Balaña, C
Izquiredo, M
Herrero, A
del Campo, JM
Cervantes, A
Poveda, A
Bover, I
Casado, A
Arcusa, A
ANNALS OF ONCOLOGY, 2000, 11 : 85 - 85

← 1 2 3 4 5 →